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ABSTRACT
The signal recognition particle (SRP) provides the
molecular link between synthesis of polypeptides and
their concomitant translocation into the endoplasmic
reticulum. During targeting, SRP arrests or delays
elongation of the nascent chain, thereby presumably
ensuring a high translocation efficiency. Components
of the Alu domain, SRP9/14 and the Alu sequences of
SRP RNA, have been suggested to play a role in the
elongation arrest function of SRP. We generated a
truncated SRP14 protein, SRP14–20C, which forms,
together with SRP9, a stable complex with SRP RNA.
However, particles reconstituted with SRP9/14–20C,
RC(9/14–20C), completely lack elongation arrest
activity. RC(9/14–20C) particles have intact signal
recognition, targeting and ribosome binding activities.
SRP9/14–20C therefore only impairs interactions with
the ribosome that are required to effect elongation
arrest. This result provides evidence that direct inter-
actions between the Alu domain components and the
ribosome are required for this function. Furthermore,
SRP9/14–20C binding to SRP RNA results in tertiary
structure changes in the RNA. Our results strongly
indicate that these changes account for the negative
effect of SRP14 truncation on elongation arrest, thus
revealing a critical role of the RNA in this function.
INTRODUCTION
In cells, secretory and membrane proteins have to be translocated
into the endoplasmic reticulum (ER) for their final dispatching.
The signal recognition particle (SRP) is a cytoplasmic ribonucleo-
protein complex that is a crucial component in this process. On
the basis of biochemical studies, a model of the functional cycle
of mammalian SRP has been elaborated (for recent reviews 1–3).
SRP recognizes and binds co-translationally to signal sequences
present in nascent chains of secretory and membrane proteins.
This interaction causes an arrest or a delay in elongation of the
nascent chains. The SRP–nascent chain–ribosome complex is
then targeted to the ER via an interaction between SRP and an ER
membrane protein complex, the SRP receptor. Once the nascent
chain–ribosome complex becomes bound to the translocon, the
SRP–SRP receptor complex is released from the ribosome,
protein synthesis resumes and the protein is translocated co-
translationally across or into the ER membrane. SRP then
dissociates from the receptor and is free to engage in another
targeting round. SRP-mediated targeting is regulated by GTP
binding and hydrolysis of three GTPases, SRP54 and both
subunits of the SRP receptor. GTP binding of SRP54 was found
to be stimulated by a ribosomal component (4), indicating a
regulatory link between translation and translocation.
Mammalian SRP is composed of an RNA molecule of 300 nt
and six polypeptides named according to their molecular weight.
Reconstitution of subparticles in vitro has allowed assignment of
the signal recognition and targeting functions to specific components
of SRP. SRP(S), a subparticle composed of SRP54, SRP19,
SRP68/72 and the central domain of SRP RNA, promotes
co-translational translocation of proteins (5), whereas the same
subparticle without SRP68/72 allows constitutive translocation
of elongation-arrested nascent chains (6).
Elongation arrest activity of SRP requires the presence of all
SRP subunits and is detected as a complete arrest or as a pause in
elongation of nascent chains bearing a signal sequence in a wheat
germ translation system. The arrest or pause is released in the
presence of salt-washed mammalian microsomes to allow
translocation of the nascent polypeptide. In reticulocyte lysate,
SRP effects a kinetic delay in the accumulation of full-length
polypeptide (7). Molecular analysis of the translation process has
shown that ribosomes pause naturally at specific sites on mRNAs
and that SRP enhances pausing at these sites during synthesis of
ER-targeted proteins (8). A mathematical model describing the
effects of SRP on translocation predicts that an extended pause in
elongation would suffice to attach ribosomes with maximal
efficiency to the ER membrane in vivo, thereby presumably
preventing misfolding and aggregation of newly synthesized
polypeptides into a translocation-incompetent form (9).
Elongation arrest activity implies a direct interaction between
the translational machinery and SRP. In vitro, two modes of
interaction between SRP and ribosomes can be distinguished
*To whom correspondence should be addressed. Tel: +41 22 702 6724; Fax: +41 22 781 1747; Email: strub@cellbio.unige.ch
1921
Nucleic Acids Research, 1994, Vol. 22, No. 1Nucleic Acids Research, 1997, Vol. 25, No. 10 1921
based on their different sensitivities to salt (6,10). The formation
of high salt-resistant complexes is due to interactions between
SRP54 and the signal sequence. Formation of complexes that are
stable at physiological and lower salt concentrations requires
complete SRP and ribosomes with or without a nascent chain.
Thus, these complexes reveal direct interactions between the
ribosome and SRP. Interestingly, SRP54 can be cross-linked to a
non-functional signal sequence and can be loaded with GTP by
a ribosomal component in these complexes (4,6), suggesting that
positioning of SRP on the ribosome is independent of the
presence of a functional signal sequence. Genetic experiments
confirmed a direct interaction between SRP and the ribosome and
indicated that it occurs at a specific step in the elongation cycle,
just before the peptidyl-tRNA undergoes translocation from the
A to the P site of the ribosome (11).
How SRP interacts with the ribosome to effect elongation arrest
remains to be elucidated. Since elongation arrest activity can only
be observed with complete SRP, positive evidence for the specific
role of a SRP subunit in this activity cannot be obtained by
reconstituting subparticles. The Alu domain of SRP, composed of
the Alu sequences at the 5′- and 3′-ends of SRP RNA and the
heterodimer SRP9/14, has been suggested to play an essential role
in this function based on the observation that its removal or
removal of the heterodimer SRP9/14 abolishes the elongation
arrest function of the particle (12,13). The same particles were later
found to be defective in low salt, signal sequence-independent
binding to ribosomes (6,10). This finding may indicate an
important role of the Alu domain in ribosome binding or may
reveal a more general defect of the particle which may indirectly
account for the observed loss of elongation arrest activity.
To define more conclusively the components and the nature of
the interactions essential for elongation arrest function, we
decided to search for a mutant SRP9/14 protein that specifically
interferes with elongation arrest activity of the particle. Mammalian
SRP9 and SRP14 proteins form a stable heterodimer and it is the
heterodimer which binds specifically to SRP RNA (14). Here we
report the characterization of a truncated SRP14 protein which
assembles efficiently into SRP and concomitantly abolishes
elongation arrest activity of the reconstituted particles. All other
functions of the mutant particle comprising the truncated SRP14
protein are the same as for particles comprising wild-type SRP14.
Our results provide convincing evidence for a direct role of the
Alu domain in effecting elongation arrest. Using hydroxyl
radicals as a probe for RNA structure, we found that the
heterodimer comprising the truncated SRP14 protein induces
changes in the structure of SRP RNA as compared with the
wild-type complex. This finding suggests a model in which
truncation of the SRP14 protein interferes with elongation arrest
activity by changing the tertiary structure of the Alu portion of
SRP RNA.
MATERIALS AND METHODS
SP6 RNA polymerase and RNase inhibitor (RNasin) were
purchased from Biofinex and DNA ligase from New England
Biolabs. Restriction enzymes were obtained from New England
Biolabs and Fermentas. The T4 polynucleotide kinase was
bought from Fermentas. The plasmids pET-3a, pET-3b and
pET-9a were from Invitrogen. Ribonucleotide triphosphates were
obtained from Pharmacia LKB Biotechnology and [γ-32P]ATP
(5000 Ci/mmol) and [35S]methionine (1500 Ci/mmol) from
Amersham Life Science. Avian myeloblastosis virus reverse
transcriptase and Escherichia coli tRNA were purchased from
Boehringer Mannheim. CM and heparin–Sepharose resins were
obtained from BioRad.
Expression, purification and RNA binding assay of the
recombinant heterodimers and SRP19
For expression of SRP9/14 and SRP9/14–20C in E.coli, we
engineered pET plasmids (15) that carry the coding regions for
the two polypeptides in two independent T7 transcription units
arranged in tandem on the same plasmid. To this end, we
introduced an NdeI site at the initiator ATG of SRP14–20C cDNA
by the polymerase chain reaction (PCR) and ligated the amplified
fragment, which was digested with NdeI and BamHI, into the
linearized plasmid pET-9a (pE14–20C). The SRP14–20C cDNA
and the adjacent T7 promoter and terminator sequences were then
amplified from the pE14–20C plasmid using an oligonucleotide
complementary to vector sequences comprising the BglII site and
another oligonucleotide that introduces a BclI site at the EcoRV
site in pET-9a. The amplified DNA was digested with BclI and
BglII and inserted into the BglII site of the pE9C plasmid (16),
resulting in plasmid pE14–20C-9dim. A similar construct was
made for expression of SRP9 and SRP14 and is described
elsewhere (17). SRP9 was more highly expressed than SRP14
from both plasmids. For expression of SRP19, we introduced a
NdeI restriction site at the initiator ATG of the SRP19 cDNA by
PCR using plasmid pG19 (18). The amplified fragment was
digested with the restriction enzymes NdeI and BamHI and
inserted into pET-3b linearized with the same enzymes. The
coding regions of all expression plasmids were sequenced. The
two heterodimers SRP9/14 and SRP9/14–20C and SRP19 were
expressed for 3 h in BL21(DE3) cells by the addition of 1 mM
IPTG. Bacterial pellets were resuspended in 50 mM Tris, pH 7.5,
50 mM sodium chloride, 10 mM EDTA, 10% glycerol, 10 mM
magnesium chloride, 10 mM dithiothreitol (DTT), 1 mM
phenylmethylsulfonyl fluoride, 0.5 µg/ml aprotinin and 500 mM
ammonium chloride was added before lyzing the bacteria in a
French press. After lysis, the ammonium chloride concentration
was adjusted to 250 mM and cell debris was removed by
centrifugation at 4C for 10 min at 30 000 g. Polymin P was
added at a final concentration of 0.05%, nucleic acids were
allowed to precipitate for 30 min at 4C and then removed by
centrifugation at 30 000 g for 20 min. Proteins were purified from
the supernatants by heparin and CM chromatography. The excess
of SRP9 over SRP14–20C was removed from the heterodimer on
the CM column. Fractions containing the purified proteins were
pooled and dialyzed against 500 mM potassium acetate, pH 7.5,
20 mM HEPES–KOH, pH 7.5, 5 mM magnesium acetate, 0.01%
Nikkol, 10% glycerol and 1 mM DTT (HKMDN + glycerol). The
proteins were quantified by comparison with canine SRP on a
Coomassie stained gradient SDS–polyacrylamide gel. For complex
formation, the two components (45 pmol SRP RNA and 30 pmol
SRP9/14 or SRP9/14–20C) were combined in 50 µl HKMDN
containing 200 mM potassium acetate under reconstitution
conditions. The complexes were fractionated on linear 10–31%
glycerol gradients at 40 000 g for 15 h. The RNA was analyzed
on 6% urea–polyacrylamide gels and visualized by ethidium
bromide staining. The proteins were analyzed by SDS–PAGE and
SRP14 visualized by immunoblotting with affinity purified
anti-SRP14 antibodies. The recombinant SRP19 protein is shown
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Figure 1. Recombinant SRP proteins used for in vitro reconstitution of particles. (A) Truncation of SRP14 by 20 amino acids removes a highly conserved region. The
alignment of SRP14 protein sequences from mouse (23), the plants Arabidopsis thaliana (Arabid) and Oryza sativa (rice) (N.Bui, N.Wolff and K.Strub, unpublished
results; accession nos: A.thaliana, Y10116; O.sativa, Y10118) and Saccharomyces cerevisiae (yeast) (35) are shown in the region spanning amino acids 83–110 in
murine SRP14. Black, completely conserved amino acids; gray, amino acids with similar physicochemical properties. In SRP14–20C Met 91 was replaced with a stop
codon (*). (B) Coomassie stained gel of recombinant human SRP19 (lane 1) used in the reconstitution experiments, recombinant mouse SRP9/14 (lane 3) and canine
SRP (lane 2). (C) Recombinant SRP9/14–20C (lane 2) and canine SRP (lane 1). SRP9 and SRP14–20C migrate at almost identical positions. Immunoblot of
SRP9/14–20C using antibodies against the fusion protein SRP9/14 (lane 3) and affinity purified anti-SRP14 antibodies (lane 4). As expected from the comparison
with canine SRP9 (lanes 1 and 2), SRP14 was identified as the slower migrating protein. (D and E) RNA binding capacities of SRP9/14 and SRP9/14–20C. Complexes
between SRP RNA and SRP9/14 and SRP9/14–20C were formed in vitro and fractionated on linear 10–31% glycerol gradients. A total of 15 fractions was collected
and analyzed for RNA and protein content. (Upper panels) SRP14 visualized by immunoblotting with affinity purified anti-SRP14 antibodies. (Lower panels) SRP
RNA revealed on ethidium bromide stained sequencing gels. I, protein samples and in vitro synthesized SRP RNA used in the experiments.
in Figure 1 and its biological activity was confirmed by the
experiments shown in Figure 2.
Elongation arrest and translocation assays
SRP was reconstituted from the recombinant proteins described
above together with SRP RNA and canine SRP68/72 and SRP54.
SRP RNA was produced as described (19). Canine SRP68/72 and
SRP54 were purified as described in Siegel and Walter (5).
Reconstitution of SRP was done in 6 µl at a 0.5 µM concentration
of all the constituents in HKMDN buffer by incubating for 10 min
on ice and for 10 min at 37C. RC(–9/14) was obtained by
replacing SRP9/14 with HKMDN buffer in the reconstitution
reaction. Elongation arrest activity of the particles was assayed in
10 µl wheat germ translation reactions programed with synthetic
preprolactin and sea urchin cyclin transcripts as described in
Strub and Walter (14). Translation was stopped after 20 min by
precipitating the proteins with 10% trichloroacetic acid. The
[35S]methionine-labeled proteins were analyzed by 12% SDS–
PAGE, visualized by autoradiography and quantified using
phosphorescence imaging (BioRad). To assay translocation, the
wheat germ translation reactions were carried out in the presence
of SRP-depleted canine microsomes (0.15 eq./µl) and were
allowed to continue for 1 h (5). SRP-depleted canine microsomes
were prepared as described (20). Translocation was detected by
the appearance of a faster migrating band on the gel correspon-
ding to prolactin. Elongation arrest and translocation efficiencies
were evaluated by the following calculations: EA = [1 – (PS × C0/CS
× P0)] × 100, where EA is percent elongation arrest activity, PS
and CS are the amounts of preprolactin and cyclin synthesized in
1923
Nucleic Acids Research, 1994, Vol. 22, No. 1Nucleic Acids Research, 1997, Vol. 25, No. 10 1923
Figure 2. Heterodimer SRP9/14–20C fails to confer elongation arrest activity
to the particle. SRP was reconstituted in the presence of increasing amounts of
the recombinant heterodimers SRP9/14 (A) and SRP9/14–20C (B). The
concentration of the partially reconstituted SRP lacking 9/14 [RC(–9/14)] was
37.5 nM in the translation reactions shown in lanes 1 and 3–5. The
concentrations of the recombinant heterodimers were 0 (lane 1), 37.5 (lane 3),
112.5 (lane 4) and 375 (lane 5) nM. The translation reactions shown in lane 2
were complemented with SRP buffer. (C and D) Relative inhibition of
accumulation of preprolactin as compared with cyclin. The ratio of preprolactin
to cyclin in lane 1 was taken as 0% inhibition.
the sample and P0 and C0 are the amounts of preprolactin and
cyclin synthesized in the absence of elongation arrest (SRP buffer
or SRP9/14); T = 100 × P/(pP + P), where T is percent
translocation, P is the amount of prolactin and pP is the amount
of preprolactin (5). All calcuated values represent the average of
two or more independent experiments. The experimental error is
±10% in the elongation arrest assay.
Ribosome binding assay
Binding assays were performed as described (10). Truncated
transcripts encoding the first 143 amino acids of PAI-2 (-hB,
I8/I14 in 21) (PAI-2/143) and encoding the first 130 amino acids
of cyclin (cycl/130) were generated by digestion of PAI-2-I8 I14
(pDB5909) and cyclin (pcyclin) cDNAs with SspI and PstI
respectively, followed by transcription with SP6 RNA polymerase.
Wheat germ translations (10 µl) containing [35S]methionine were
performed in the absence and presence of the truncated transcripts
PAI-2/143 and cycl/130 for 20 min at 26C. The stable
ribosome–nascent chain complexes were purified by pelleting
through a sucrose cushion (150 µl) containing 50 mM HEPES,
pH 7.5, 500 mM KOAc, 2.5 mM Mg(OAc)2, 1 mM DTT, 0.01%
Nikkol, 0.25 mM CH and 0.5 M sucrose. After centrifugation in
a Centrikon TFT 80.2 rotor at 70 000 r.p.m. for 60 min at 4C, the
pellets were resuspended in 10 µl buffer (RSB) containing 50 mM
HEPES, pH 7.5, 50 mM KOAc, 2.5 mM Mg(OAc)2, 1 mM DTT,
0.01% Nikkol, 0.25 mM CH. The supernatants were kept for
analysis (S1). Reconstituted SRP samples (1 pmol) were added
to the ribosomes and incubated for 10 min at 26C and for 1 h on
ice. The volumes of the samples were adjusted to 50 µl using RSB
(final [KOAc] = 70 mM) prior to centrifugation through a 150 µl
sucrose cushion as described above. The supernatants (S1 and S2)
and the pellets (P) were analyzed by 12 and 15% SDS–PAGE.
Nascent chains were visualized by autoradiography and proteins
were detected by immunoblotting with anti-SRP68 and anti-SRP14
antibodies. Western blots were revealed using the Enhanced
Chemiluminescence system (Amersham).
Hydroxyl radical cutting reactions
The cleavage reactions were carried out as described (19). For
milder cleveage reaction the concentrations of ferrous ammonium
sulfate and EDTA were reduced to one half, 12.5 and 25 mM
respectively. SRP RNA (0.1 pmol) and SRP9/14 were combined
at three different RNA:protein ratios (1:5, 1:10 and 1:50) in 3 µl
HKMDN buffer. In the negative control, SRP9/14 was replaced
by the same amount in weight of bovine serum albumin (BSA).
RNA fragments were phenol/chloroform extracted and ethanol
precipitated. Pellets were resuspended and annealed to 0.3 pmol
32P-labeled primer in 12 µl annealing buffer (AB) containing
50 mM Tris, pH 8.5, 30 mM KCl for 3 min at 65C and 30 min
at 42C. Reverse transcription was carried out by combining 2 µl
primer/template sample, 1 µl 2 mM dNTPs in AB, 1 µl ddNTPs
or AB (either 0.4 mM ddATP, 0.4 mM ddGTP, 0.2 mM ddCTP
or 0.125 mM ddTTP for the sequencing reactions) and 1 µl
reverse transcriptase (1.6 U) in 50 mM Tris, pH 8.5, 40 mM
MgCl2, 150 mM KCl, 5 mM DTT. After an incubation of 1 h at
50C, reactions were stopped by addition of 4 µl denaturing
sample buffer and the extension products separated on 8%
sequencing gels.
RESULTS
SRP9/14–20C competes with SRP9/14 for binding to SRP
RNA and lacks the capacity to confer elongation arrest
activity to the particle
To examine the role of SRP9/14 in the elongation arrest function
of SRP, we decided to search for mutant SRP9 and SRP14
proteins that had specifically lost their capacity to confer
elongation arrest activity to the particle. However, the altered
proteins would still dimerize with the partner protein and form
stable complexes with SRP RNA. A previous analysis had shown
that 10 amino acids at the C-termini of murine proteins SRP9 and
SRP14 were dispensable for RNA binding and for elongation
arrest activity of the particle (22). Analysis of the RNA binding
capacities of truncated SRP14 proteins (36), together with
experiments in which the truncated SRP14 proteins were assayed
for their capacities to confer elongation arrest activity to SRP
particles (results not shown), indicated that the heterodimer
comprising an SRP14 protein lacking the C-terminal 20 amino
acids, SRP9/14–20C, may have the wanted phenotype. Hence,
we decided to produce large amounts of the heterodimers
SRP9/14–20C and, as a positive control, SRP9/14 in bacteria to
study the effect of SRP9/14–20C on SRP functions in more detail.
To express SRP14–20C, we introduced a stop codon into the
SRP14 cDNA which replaced Met91 in the SRP14 protein
(Fig. 1A). This truncation removes a highly conserved region in
SRP14. SRP9/14–20C and SRP9/14 were overproduced in
bacteria by simultaneous expression of SRP9 and SRP14 proteins
from two independent, tandemly arranged, T7 polymerase-
controlled transcription units (Materials and Methods). SRP9 was
more highly expressed than SRP14 from both plasmids. The
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purified proteins SRP9/14 and SRP9/14–20C are shown in Figure 1.
Mouse SRP9 co-migrated with canine SRP9, whereas mouse
SRP14 migrated slightly slower than canine SRP14 (Fig. 1B,
lanes 2 and 3), possibly, because it still contains the initiator
methionine which is removed in canine SRP14 (23). The SRP9
and SRP14–20C proteins migrated in close proximity (Fig. 1C,
lane 2). However, the SRP14–20C protein could be visualized
individually by immunoblotting with affinity purified anti-SRP14
antibodies (Fig. 1C, lane 4). The heterodimers were assumed to
have an equimolar composition based on the following criteria:
(i) equal intensities of Coomassie stained SRP9 and SRP14
protein bands; (ii) the excess of SRP9 was removed during ion
exchange chromatography (Materials and Methods); (iii) no
excess of free SRP14 protein could be detected in the RNA
binding experiments discussed below.
To confirm the RNA binding activity of the recombinant
heterodimer, SRP9/14–20C was bound at 200 mM potassium
acetate to SRP RNA and the free and RNA-bound proteins were
separated on 10–31% glycerol gradients. Based on the purification
procedure, we could not entirely exclude the possibility that the
heterodimeric protein samples contained an excess of SRP14
protein. In addition, SRP9 and SRP14–20C co-migrate on
SDS–PAGE. We therefore chose to analyze the proteins by
immunoblotting with anti-SRP14 antibodies. The RNA content
was revealed by ethidium bromide staining (Fig. 1D and E).
SRP9/14–20C and the positive control SRP9/14 co-migrated
with SRP RNA in fractions 8–11, demonstrating that they were
bound to the RNA. Free proteins migrate in the uppermost
fractions in these gradients (24), whereas free RNA migrates at
a similar position to the RNA–protein complex because of the
small difference in molecular mass between free RNA and the
complex (100 and 122 kDa respectively). Thus, the RNA:protein
ratio in the different fractions was determined by the presence of
free RNA and RNA–protein complex. The apparent absence of
SRP RNA in the flanking fractions where the protein could be
detected is most likely explained by a lower sensitivity of
detection of the RNA. As expected from the previous findings
that neither protein alone binds to SRP RNA (14), we detected a
single broad protein band co-migrating with SRP RNA in silver
stained gels of SRP9/14–20C glycerol gradients; consistent with
co-migration of SRP9 and SRP14–20C.
The recombinant proteins were then used in complementation
and competition experiments. Mammalian SRP can be reconstituted
in vitro from the canine proteins SRP68/72, SRP54 and SRP19,
murine SRP9/14 and in vitro synthesized SRP RNA (16). The
elongation arrest activities of the reconstituted particles was
subsequently assayed by quantifying their specific effect on
synthesis of a secretory protein standardized to synthesis of a
cytosolic protein. In the following reconstitution experiments,
canine SRP19 was substituted by human SRP19 produced in
bacteria (see Materials and Methods and Fig. 1B). Equimolar
amounts of SRP components were combined in the presence of
increasing concentrations of either SRP9/14 or SRP9/14–20C
and the reconstituted particles were added to translation reactions
programed with synthetic preprolactin and cyclin transcripts to
determine elongation arrest activity (Fig. 2). As a negative
control, the translation reactions contained either buffer or a
partially reconstituted particle lacking SRP9/14, which we called
RC(–9/14) to distinguish reconstituted particles from proteins.
RC(–9/14) is deficient in elongation arrest activity (5). The
concentrations of the SRP components in the translation reactions
was 37.5 nM, whereas the concentrations of SRP9/14 and
SRP9/14–20C were equimolar (lane 3), 3- (lane 4) and 10-fold
(lane 5) higher than the concentrations of the other SRP
components. The 35S-labeled proteins were displayed by SDS–
PAGE (Fig. 2A and B) and quantified using phosphorescence
imaging. The relative accumulation of preprolactin as compared
with cyclin in the different samples was standardized to its
relative accumulation in the presence of RC(–9/14) (Materials
and Methods).
In the positive control, SRP9/14 conferred maximal elongation
arrest activity to the particle at equimolar concentrations of the
protein, thereby confirming the biological activity of the purified
heterodimeric protein (Fig. 2A and C). Increasing concentrations
of SRP9/14 had no additional effect on preprolactin synthesis.
Furthermore, this effect was specific for reconstituted SRP, since
in parallel control experiments, in which SRP9/14 was added to
the translation reactions in the absence of RC(–9/14), the ratio
between preprolactin and cyclin synthesis remained the same
(results not shown). In contrast to SRP9/14, SRP9/14–20C failed
to complement RC(–9/14) for its lack of elongation arrest activity,
even in the presence of a 10-fold excess of the heterodimeric
protein over the other SRP components (Fig. 2B and D). In some
experiments we observed an increase in cyclin and preprolactin
synthesis upon addition of SRP9/14–20C or of a large excess of
SRP9/14 (Fig. 2A and B). However, since the ratio of cyclin to
preprolactin synthesis was unchanged, it remained within the
10% error limit, as for RC(–9/14) (Fig. 2D), this effect did not
interfere with interpretation of our results.
In competition experiments, SRP components, including
SRP9/14, were combined at an equimolar ratio in the presence of
increasing SRP9/14–20C concentrations. The SRP samples were
then added to translation reactions programed with synthetic
preprolactin and cyclin transcripts. We found that increasing
concentrations of the competitor, SRP9/14–20C, resulted in
diminished elongation arrest activity of the particle (Fig. 3). This
effect was specific for reconstituted SRP, since increasing
concentrations of SRP9/14–20C in the absence of RC(9/14)
during translation had no effect on synthesis of full-length
preprolactin and cyclin (results not shown). Hence, these results
provide evidence that assembly of SRP9/14–20C into the particle
caused the defect in elongation arrest function of the particle. The
competition experiments also confirmed the capacity of
SRP9/14–20C to bind to the RNA, albeit at a slightly reduced
efficiency as compared with SRP9/14. A 5-fold excess of
SRP9/14–20C over SRP9/14 was required to reduce elongation
arrest activity of the particle 2-fold (Fig. 3, lanes 1 and 4).
However, because of the uncertainty associated with the con-
centrations of the heterodimers, the exact difference in affinity
was not quantified.
RC(9/14–20C) is functional in translocation and in direct,
signal sequence-independent ribosome binding
Next, we wanted to examine whether particles containing
SRP14–20C, RC(9/14–20C), exclusively lack elongation arrest
activity or whether they have other functional defects. The three
other functions of SRP that can be studied in vitro are the signal
recognition and targeting functions and the capacity of SRP to
bind to ribosomes directly in a signal sequence- and nascent
chain-independent fashion.
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Figure 3. Heterodimer SRP9/14–20C competes efficiently with wild-type
SRP9/14 for assembly into SRP and concomitantly abolishes elongation arrest
activity of the particle. (A) All SRP components, including SRP9/14, were
combined at 0.5 µM each in the presence of increasing concentration of
SRP9/14–20C: 0 (lane 1), 0.5 (lane 2), 1.25 (lane 3), 2.5 (lane 4), 3.75 (lane 5)
and 5 (lane 6) µM. The negative control, RC(–9/14), is shown in lane 7. The
final concentration of the reconstituted particles in the translation reactions was
50 nM. (B) Relative inhibition in accumulation of preprolactin as compared
with cyclin. RC(–9/14) in lane 7 was taken as a standard for 0% inhibition.
To examine the signal recognition and targeting activities of
RC(9/14–20C), we determined its capacity to promote translocation.
SRP(S), which comprises the S portion of SRP RNA, SRP19,
SRP54 and SRP68/72, and RC(–9/14) have both been shown to
be functional in signal recognition and targeting and to translocate
secretory proteins into the ER co-translationally, albeit at an
efficiency 50% lower than that of complete canine SRP (5,6,12).
If RC(9/14–20C) was functional in signal recognition and
targeting, we would expect it to promote co-translational
translocation at least as efficiently as RC(–9/14). To determine its
capacity to promote translocation, different SRP samples were
reconstituted in vitro and added individually to translation
reactions programed with preprolactin and cyclin synthetic
mRNAs and complemented with SRP-depleted canine microsomes.
SRP-depleted canine microsomes are translocation incompetent in
the absence of exogenously added SRP. The products of the
translation/translocation experiments were analyzed by SDS–
PAGE. The translocation efficiencies of the different samples
were compared with the translocation efficiency of canine SRP
(Fig. 4). The positive control, canine SRP, promoted translocation
of preprolactin at an efficiency of 75%. As previously observed
(25), fully reconstituted SRP, RC(9/14), was slightly less
effective in promoting translocation of preprolactin than canine
SRP. Notably, RC(9/14–20C) had the same translocation capacity
as RC(–9/14), demonstrating that these particles are functional in
signal recognition and in targeting of nascent chain–ribosome
complexes (Fig. 4, lanes 2 and 4). In addition, this result
confirmed the presence of SRP68/72 within the particle, since in
its absence only elongation-arrested nascent chains are translocated
(6).
Figure 4. Signal recognition and targeting functions are intact in
RC(9/14–20C). (A) Translocation of preprolactin was assayed in the presence
of the different reconstituted samples as indicated at the top of each lane.
SRP-depleted canine microsomes were present in all samples at 0.15
equivalents/µl. (B) The preprolactin (pPI) to prolactin (PI) ratio was determined
as described in Materials and Methods. Buffer, SRP sample was replaced by
buffer; RC(–9/14), particles lacking SRP9/14; SRP, canine SRP; RC(9/14) and
RC(9/14–20C), particles reconstituted with SRP9/14 and SRP9/14–20C
respectively.
Two modes of interaction between SRP and ribosomes can be
distinguished by their sensitivities to salt concentration. The high
salt-resistant interactions reflect signal sequence-dependent binding
of SRP to ribosome–nascent chain complexes. Ribosome binding
of SRP at physiological or lower salt concentrations is independent
of nascent chains (10) and reflects direct interactions between the
ribosome and SRP. SRP binding to ribosomes at low salt was
found to be very sensitive to omission of single SRP subunits,
since it required the presence of all SRP components (10). Based
on these results, SRP binding to ribosomes at low salt concentrations
provides a very sensitive assay to detect changes in the molecular
interactions of SRP and ribosomes.
Hence, we examined the capacity of RC(9/14–20C) to bind in
a nascent chain-independent fashion to ribosomes. As an
alternative for a secretory protein we used plasminogen activator
inhibitor-2 with an altered signal sequence, PAI-2-I8I14. This
protein has previously been shown to translocate efficiently in
vitro (21). Cyclin was used as a cytoplasmic protein. The
elongation-arrested nascent chains of PAI-2-I8I14 and cyclin
comprised 143 and 130 amino acid residues respectively. Wheat
germ ribosomes alone and associated with nascent chains of
PAI-2-I8I14 and cyclin were purified by centrifugation through a
high salt sucrose cushion. This procedure removes the nascent
polypeptide-associated complex (26) as well as non-ribosomal
wheat germ proteins from the ribosomes. The nascent polypeptide-
associated complex has been found to modulate signal sequence-
independent interactions between SRP and the ribosome (10).
The supernatants of the centrifugation (Fig. 5, S1) were included
in the analysis described below. The ribosomes and the nascent
chain–ribosome complexes found in the pellet were resuspended
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Figure 5. RC(9/14–20C) preserved its capacity to bind directly in a nascent
chain-independent fashion to ribosomes. Ribosomes alone (A) and associated
with truncated cyclin (B) and truncated PAI-2-I8I14 (C) were sedimented
through high salt sucrose cushions to remove NAC. Binding of different
particles to salt-washed ribosomes was assayed by sedimenting the complexes
through sucrose cushions at a salt concentration of 70 mM potassium acetate
(Materials and Methods). S1 and S2, supernatants of first and second
centrifugations; P, ribosomal pellet; Cycl and PAI-2-I8I14, 35S-labeled nascent
chains of a cytosolic and a secretory protein respectively. SRP68 and SRP14
proteins were revealed by immunoblotting. RC(9/14) and RC(9/14–20C),
reconstituted particles comprising SRP9/14 and SRP9/14–20C proteins
respectively; RC(–9/14), particles lacking SRP9/14.
and incubated with RC(9/14) and with RC(9/14–20C) at a final
salt concentration of 70 mM potassium acetate. As a negative
control, we also included RC(–9/14) in the binding experiments
with ribosomes alone. Binding of the different reconstituted
particles to the ribosomes was monitored by centrifugation of the
complexes through a sucrose cushion. Bound particles would
sediment with the ribosomes into the pellet (Fig. 5, P), whereas
unbound particles would be found in the low density fractions
(Fig. 5, S2). Sedimentation of the ribosomes is revealed by the
presence of elongation-arrested nascent chains in the pellet (Fig. 5B
and C).
The different samples were displayed by SDS–PAGE and
analyzed by autoradiography and by immunoblotting with
anti-SRP68 and anti-SRP14 antibodies. Immunoblotting with
anti-SRP68 antiserum indicated that the positive control sample,
RC(9/14), and the experimental sample, RC(9/14–20C), sedimented
together with the ribosomes in both the absence and presence of
nascent chains (Fig. 5A–C). The anti-SRP68 antiserum showed
cross-reactivity with a slightly larger protein in wheat germ
extract (Fig. 5, S1). However, the cross-reactive protein did not
sediment with the ribosomes and therefore did not interfere with
the analysis. Association of the particles with the ribosomes as
well as the presence of the SRP14 proteins within the particles
were confirmed using affinity purified anti-SRP14 antibodies in
the Western blot analysis shown in Figure 5A. The negative
control, RC(–9/14), was defective in ribosome binding and was
found in the supernatant of the gradient (Fig. 5A), in agreement
with previous results (10).
These results demonstrated that RC(9/14–20C) and RC(9/14)
have a comparable capacity to bind directly to ribosomes in a
signal sequence-independent fashion. Thus, the removed region
is not critical for SRP binding to ribosomes; its absence
specifically impairs interactions with the ribosome that are
required to effect elongation arrest.
Hydroxyl radical probing of SRP RNA complexes with
SRP9/14 and SRP9/14–20C
The slightly different affinities of the two heterodimers for SRP
RNA in the competition experiments suggested that subtle
changes in protein–RNA interactions exist. RNA cleavage by
hydroxyl radicals has previously been used to study the canine
SRP9/14–SRP RNA complex (19). The hydroxyl radical cleavage
reagent, which attacks the ribose backbone, is a valuable tool to
probe the tertiary structure and protein binding sites in RNA
(27,28), since it cleaves RNA independently of its secondary
structure.
SRP9/14 and SRP9/14–20C and, as a negative control, the
same amount of bovine serum albumin were incubated with SRP
RNA and exposed to the hydroxyl radical cleavage reagent
(Materials and Methods). The cleaved products were analyzed by
primer extension with reverse transcriptase. Comparison of the
cleavage patterns revealed that four sites in the Alu domain of
SRP RNA became more sensitive to hydroxyl radical cleavage in
the SRP9/14–20C–RNA complex as compared with the
SRP9/14–RNA complex (Fig. 6A). These sites are represented by
the fragments extending to positions C37/U38, C79 and A88.
Hence, the nucleotides preceding the extended products,
A36/C37, U78 and C87, became more sensitive to attack by
hydroxyl radicals. These differences were highly reproducible
and clearly visible at low protein concentration at positions C37,
U78 and C87. Higher protein:RNA ratios increased the sensitivity
at the same sites and revealed an additional hypersensitive
nucleotide, A36. To confirm that these sites were hypersensitive
to cleavage by hydroxyl radicals, we repeated the cleavage
reactions choosing milder reaction conditions. Under the modified
conditions, the reactivity was strongly diminished at all positions
except at the hypersensitive nucleotides C37 and C87 (Fig. 6B).
Again, the increased sensitivity at position A36 was exclusively
observed at higher protein:RNA ratios. The U78 position was not
hypersensitive to cleavage under milder conditions. We reproducibly
observed a considerable background in the reverse transcription
of uncleaved SRP RNA (Fig. 6A, R). Such a background has been
observed for many RNA species and is commonly thought to
result from premature termination of the reverse transcriptase
within regions with highly stable secondary structures (28,29).
However, the background does not interfere with the interpretation
of our data because: (i) it relies on comparing signals of cleaved
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RNA in the presence of different proteins; (ii) the observed
hypersensitive sites do not coincide with strong termination sites
of reverse transcriptase. In contrast, the strong signal observed at
position 46 and 47 (lane M) is most likely explained by premature
termination.
Compared with the negative control, bovine serum albumin,
the regions protected from hydroxyl radical cleavage in the
presence of SRP9/14 and of SRP9/14–20C were the same, thus
confirming that SRP9/14–20C binds efficiently to SRP RNA.
The protected regions were also similar to those reported
previously for canine SRP9/14 (19). Region I [corresponding to
region II in Strub et al. (19)] could be observed at low
protein:RNA ratios, whereas regions II and III (regions III and IV
in the previous paper) could only be detected at higher
protein:RNA ratios. Furthermore, we observed a protected region
around nt 66–70 in SRP RNA at very high protein concentrations
which has previously not been detected at lower protein:RNA
ratios. The requirement for high protein:RNA ratios for detection
of the protected regions may be explained by the different
composition of the RNA–protein complexes. Previously, we used
authentic canine SRP RNA and SRP9/14, whereas in the
experiments here we used in vitro synthesized SRP RNA and
mouse SRP9/14. In addition, hydroxyl radical cleavage reactions
were carried out at a 10-fold lower complex concentration than
the elongation arrest assays. Thus, a difference in the affinity of
the murine and canine proteins for SRP RNA could explain the
observation that higher concentrations of murine protein are
required for efficient binding to the RNA. Furthermore, we
reproducibly observed a high premature termination rate of
reverse transcriptase in the region comprising nt 40–60 in SRP
RNA, which makes it more difficult to reveal protection patterns.
In summary, we observed similar protection patterns for murine
SRP9/14 and SRP9/14–20C, as expected from their RNA binding
activities. However, significant changes in protein–RNA interac-
tions were uncovered by the appearance of hypersensitive sites in
the second stem–loop structure and in the central stem of SRP
RNA in the SRP9/14–20C–RNA complex (Fig. 6C). The same
sites lack sensitivity to the reagent in the absence of the protein,
suggesting that SRP9/14–20C induces a more open conformation
at these positions in SRP RNA.
DISCUSSION
We generated an altered heterodimeric subunit of SRP,
SRP9/14–20C, which, when assembled into the particle, specifically
lacks the capacity to confer elongation arrest activity to the
particle. The results of a functional analysis of reconstituted
particles comprising SRP9/14–20C, RC(9/14–20C), provide
conclusive evidence that direct interactions between the components
of the Alu domain of SRP and the ribosome are required to effect
elongation arrest. The loss of elongation arrest activity of
RC(9/14–20C) arises upon removing a conserved region in the
Figure 6. Alterations in the hydroxyl radical cleavage pattern of SRP RNA in
the presence of SRP9/14 and SRP9/14–20C heterodimeric proteins. (A) The
primer extension products of the cleavage reactions were displayed on an 8 M
urea–6% polyacrylamide gel. Black arrows indicate the hypersensitive sites
exclusively observed in the SRP9/14–20C complex. Numbers to the left
indicate the position of SRP RNA as deduced from a sequencing reaction run
in parallel. The hypersensitive nucleotides precede the extension products. R,
SRP RNA; B, bovine serum albumin; W, SRP9/14; M, SRP9/14–20C. Regions
numbered I–IV are protected in the presence of the proteins. Regions I–III
correspond to regions II–IV in Strub et al. (19). Region IV has not previously
been detected. (B) Cleavage pattern in the 30–40 nt region in SRP RNA using
milder hydroxyl radical cleavage conditions. (C) Secondary structure model of
the Alu portion of SRP RNA. Arrows indicate hypersensitive sites.
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C-terminal part of SRP14 comprising amino acid residues
90–100 and correlates with a conformational change in the Alu
portion of SRP RNA, as indicated by the appearance of
hypersensitive cleavage sites. Based on these results, we suggest
that truncation of SRP14 abolishes elongation arrest activity by
changing the tertiary structure of the Alu portion of SRP RNA,
thus revealing a critical role of the RNA moiety in the elongation
arrest function.
Elongation arrest activity of SRP requires the presence of all
SRP components. A role for the Alu domain and the heterodimer
SRP9/14 in elongation arrest has previously been suggested by
the absence of elongation arrest activity in reconstituted particles
lacking the complete Alu domain or SRP9/14 (12,30). Later
experiments demonstrated that the same particles were also
defective in binding directly, in a nascent chain-independent
fashion, to ribosomes (6,10). Their elongation arrest-negative
phenotype could therefore indirectly result from a more general
defect of the particle, such as the loss of its capacity to bind
directly to ribosomes.
We have previously shown that the removal of 10 amino acid
residues at the C-termini of SRP14 or SRP9 failed to interfere
with the RNA binding capacity of the heterodimer and with the
elongation arrest function of reconstituted particles (22).
SRP14–20C, which lacks 10 more amino acid residues at the
C-terminus, forms a heterodimeric complex with SRP9 that can
be purified from bacterial extracts and the heterodimer binds with
a similar, albeit slightly reduced, affinity to SRP RNA. The
particles comprising SRP9/14–20C, RC(9/14–20C), have intact
signal recognition and targeting functions and bind with a similar
efficiency to ribosomes as particles reconstituted with wild-type
SRP9/14. Based on these results, the complete loss of elongation
arrest activity of RC(9/14–20C) cannot be explained by a strongly
diminished affinity for the ribosome or by major conformational
changes within the particle. Rather, it results from loss of specific
interactions between SRP and the ribosome that are necessary to
effect elongation arrest.
An important functional role for the C-terminal region in
SRP14 is also supported by the high conservation of its amino
acid sequence in mammalian, plant and yeast SRP14 proteins
(Fig. 1). In the regions corresponding to amino acids 90–100 in
murine SRP14, five amino acid residues are completely conserved
between all known SRP14 proteins and conservative substitutions of
amino acids with similar physicochemical properties are found at
three additional positions. Thus, eight out of 10 amino acid
residues are conserved within this region, whereas the overall
conservation of amino acid residues between the murine and the
other SRP14 proteins are 50, 40 and 30% for Arabidopsis
thaliana, Oryza sativa (rice) and Sassharomyces cerevisiae
(yeast) respectively. The identity of the amino acids which play
a direct or indirect role in the elongation arrest function remains
to be determined.
How does the absence of this region interfere with elongation
arrest activity of the particle? We favor a model in which
truncation of the SRP14 protein abolishes the elongation arrest
function of the reconstituted particles through changes in the
tertiary structure of the Alu portion of SRP RNA. This model is
supported by our experimental finding that the conformation of
SRP RNA is different in the SRP9/14–20C–RNA complex as
compared with the wild-type complex. Furthermore, the slightly
reduced affinity of SRP9/14–20C for SRP RNA is consistent with
a direct or indirect role of the C-terminal domain of SRP14 in
protein–RNA interaction. Minor changes in protein–RNA interac-
tions may result in small tertiary structure changes in SRP RNA.
The model is also indirectly supported by the structure of the
heterodimeric protein complex (31). This region has been found
to contribute to the dimer interface of the heterodimeric protein.
Specifically, Gly93 and Lys95 form hydrogen bonds with amino
acid residues of SRP9 and Leu94 is part of the hydrophobic core
between the two proteins. It is therefore very unlikely that this
region also makes direct contacts with the ribosome to effect
elongation arrest.
At this moment we cannot distinguish whether the subtle
changes in protein–RNA interaction result from the loss of a
direct contact between the C-terminal domain of SRP14 and SRP
RNA or from conformational changes in the heterodimer that
indirectly interfere with RNA–protein contacts. As mentioned
before, amino acid residues 93–95 contribute to direct interac-
tions between SRP9 and SRP14 and it is feasible that their
removal changes the conformation of the heterodimer without
greatly reducing its stability and the stability of the RNA–protein
complex.
The conformational change in SRP RNA in the SRP9/14–20C–
RNA complex is indicated by the appearance of hypersensitive
sites. They are located outside the protected regions and are
specifically induced by binding of SRP9/14–20C to SRP RNA,
since they are absent in naked RNA and in the SRP9/14–RNA
complex. The structure of the RNA and the RNA–protein
complex are as yet unknown and the observed hypersensitivity
can therefore not be interpreted in exact structural terms.
However, the increased accessibility to the reagent most likely
reflects a more open structure of the RNA in the specific regions.
The nucleotides A36 and C37 are in the loop of the second
stem–loop structure. The potential for base pairing between the
loops of the first and the second stem–loop structures (Fig. 6C)
has been conserved in evolution, suggesting the existence of a
pseudoknot structure formed between the two loops (32). In fact,
it has been hypothesized that base pairing between the two loops
may result in formation of a tRNA-like structure lacking the
anticodon stem and that this structure would then interact with the
ribosome to effect elongation arrest (33,34). Interference of
SRP9/14–20C binding with the formation of a putative tRNA-
like structure is certainly an attractive hypothesis to explain the
negative effect of the more open structure in this region on
elongation arrest function.
Our results provide conclusive evidence that the components of
the Alu domain of SRP interact directly with the ribosome to
effect elongation arrest and support a crucial role of the RNA
moiety in this function. The intimate relationship between the
structure of the RNA and the structure of the protein will make it
a challenging task to determine unequivocally whether the RNA
alone or the RNA and the proteins together make direct contact(s)
with the ribosome. Maybe the interacting partners in the ribosome
will have to be identified first to answer this question.
ACKNOWLEDGEMENTS
We would like to thank Monique Fornallaz and Nicole Wolff for
their help in producing recombinant proteins, Olivier Donzé and
Didier Picard for critical reading of the manuscript, P.Walter for
his scientific advice, H.Lütcke and B.Dobberstein for anti-SRP68
antibodies and S.Holbein-Oertle for engineering the SRP19
expression plasmid. This work was supported by a grant from the
1929
Nucleic Acids Research, 1994, Vol. 22, No. 1Nucleic Acids Research, 1997, Vol. 25, No. 10 1929
Swiss National Science Foundation and by the Canton de
Genève. K.S. is a fellow of the START program of the Swiss
National Science foundation.
REFERENCES
1 Walter,P. and Johnson,A.E. (1994) Annu. Rev. Cell Biol., 10, 87–119.
2 Lütcke,H. (1995) Eur. J. Biochem., 228, 531–550.
3 Bovia,F. and Strub,K. (1996) J. Cell Sci., 109, 2601–2608.
4 Bacher,G., Lütcke,H., Jungnickel,B., Rapoport,T.A. and Dobberstein,B.
(1996) Nature, 381, 248–251.
5 Siegel,V. and Walter,P. (1985) J. Cell Biol., 100, 1913–1921.
6 Hauser,S., Bacher,G., Dobberstein,B. and Lutcke,H. (1995) EMBO J., 14,
5485–5493.
7 Wolin,S.L. and Walter,P. (1989) J. Cell Biol., 109, 2617–2622.
8 Wolin,S.L. and Walter,P. (1988) EMBO J., 7, 3559–3569.
9 Rapoport,T.A., Heinrich,R., Walter,P. and Schulmeister,T. (1987) J. Mol.
Biol., 195, 621–636.
10 Powers,T. and Walter,P. (1996) Curr. Biol., 6, 331–338.
11 Ogg,S.C. and Walter,P. (1995) Cell, 81, 1075–1084.
12 Siegel,V. and Walter,P. (1986) Nature, 320, 81–84.
13 Siegel,V. and Walter,P. (1988) Cell, 52, 39–49.
14 Strub,K. and Walter,P. (1990) Mol. Cell. Biol., 10, 777–784.
15 Studier,F.W., Rosenberg,A.H., Dunn,J.J. and Dubendorff,J.W. (1990)
Methods Enzymol., 185, 60–89.
16 Strub,K., Wolff,N. and Oertle,S. (1993) In Nierhaus,K.H., Franceschi,F.,
Subramanian,A.R., Erdmann,V.A. and Wittmann-Liebold,B. (ed.), The
Translational Apparatus. Plenum Press, New York, NY, pp. 635–645.
17 Bovia,F., Wolff,N., Ryser,S. and Strub,K. (1997) Nucleic Acids Res., 25,
318–325.
18 Lingelbach,K., Zwieb,C., Webb,J.R., Marshallsay,C., Hoben,P.J., Walter,P.
and Dobberstein,B. (1988) Nucleic Acids Res., 16, 9431–9442.
19 Strub,K., Moss,J. and Walter,P. (1991) Mol. Cell. Biol., 11, 3949–3959.
20 Walter,P. and Blobel,G. (1983) Methods Enzymol., 96, 84–93.
21 Belin,D., Bost,S., Vassalli,J.-D. and Strub,K. (1996) EMBO J., 15,
468–478.
22 Bovia,F., Bui,N. and Strub,K. (1994) Nucleic Acids Res., 22, 2028–2035.
23 Strub,K. and Walter,P. (1989) Proc. Natl. Acad. Sci. USA, 86, 9747–9751.
24 Bovia,F., Fornallaz,M., Leffers,H. and Strub,K. (1995) Mol. Biol. Cell, 6,
471–484.
25 Walter,P. and Blobel,G. (1983) Cell, 34, 525–533.
26 Wiedmann,B., Sakai,H., Davis,T.A. and Wiedmann,M. (1994) Nature, 370,
434–440.
27 Latham,J.A. and Cech,T.R. (1989) Science, 245, 276–282.
28 Lentzen,G., Moine,H., Ehresmann,C., Ehresmann,B. and Wintermeyer,W.
(1996) RNA, 2, 244–253.
29 Stern,S., Moazad,D. and Noller,H.F. (1988) Methods Enzymol., 164,
481–489.
30 Siegel,V. and Walter,P. (1988) EMBO J., 7, 1769–1775.
31 Birse,D.E.A., Kapp,U., Strub,K., Cusack,S. and Åberg,A. (1997) EMBO
J., in press.
32 Zwieb,C., Müller,F. and Larsen,N. (1996) Folding Design, 1, 315–324.
33 Zwieb,C. (1985) Nucleic Acids Res., 13, 6105–6124.
34 Walter,P. and Lingappa,V.R. (1986) Annu. Rev. Cell Biol., 2, 499–516.
35 Brown,J.D., Hann,B.C., Medzihradszky,K.F., Niwa,M., Burlingame,A.L.
and Walter,P. (1994) EMBO J., 13, 4390–4400.
36 Bui,N., Wolff,N., Cusack,S. and Strub,K., RNA, in press.
